phase readout
saveNCT07298408: Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study
community read0 votes
Sponsor: Florida A&M University. Phase: PHASE1. Conditions: Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies
view source ↗Data sources
last refreshed 8h ago
Found something off?
same company · ±60 days · 6
- earningsJazz Pharmaceuticals plc earningsAug 4, 2026
- earningsJazz Pharmaceuticals plc earningsAug 3, 2026
- earningsJazz Pharmaceuticals plc earningsMay 5, 2026
- phase 2 initiationdurvalumab: Jazz Pharmaceuticals Plc — durvalumab (Phase II Trial Initiation)Apr 25, 2026
- approvallurbinectedin: ZEPZELCA (LURBINECTEDIN) — FDA approvalFeb 27, 2026
- approvallurbinectedin: ZEPZELCA (LURBINECTEDIN) — FDA approvalOct 2, 2025
related news · 8
- biospace8 companies hiring in North Carolina now
- fiercebiotechBioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
- biospaceBioSpace 2027 Best Places to Work shines light on most admired employers
- biospace6 potential blockbusters that could pave China’s path to 2030 ambitions
- biospaceNew biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs
- endpointsSetara gets $90M to continue rare disease pipeline spun out of Jazz's Actio deal
- biopharma diveWith Setara, the team behind Actio opens its second act
- fiercebiotechJazz's $820M Actio buyout gives rise to Setara, armed with $90M series A
comments(0)
5-min edit window · permanent after that